Protocol Title: A Phase 2 Open-label Study to Evaluate the Safety and Pharmacokinetics of MK-8527 Oral Once-monthly in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of HIV-1 Exposure

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is confirmed human immunodeficiency virus (HIV)-uninfected * Is a transgender or gender diverse (TGD) person, ie, a person whose gender identity differs from the sex that was assigned at birth * Is on stable gender-affirming hormone therapy (GAHT) and does not intend to change therapy through 2 months after the last dose of study intervention * Has a low likelihood of HIV exposure Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has evidence of acu…